News

Lilly’s experimental obesity drug shows promise in early study
An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the ...
Eli Lilly’s early-stage obesity drug causes up to 11% of weight loss in three months
Eli Lilly's (LLY) experimental obesity drug, eloralintide, shows up to 11% weight loss in 12 weeks with minimal side effects in early-stage trial. Read more here.
Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial
Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...
Eli Lilly telehealth partners continue to sell compounded GLP-1 weight-loss drugs despite agreement not to
Compounded GLP-1s are still accessible on telehealth sites, despite an agreement with Eli Lilly to cease copycat sales.
BioPharma Dive4d
Scorpion, fresh off Lilly deal, spins out startup Antares
Five months after selling a cancer drug to Lilly for up to $2.5 billion, Scorpion has debuted a successor company led by its ...
Roche’s Chugai Seeks Next Milestone after Finding Success with Eli Lilly’s Obesity Drug
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.